Novartis was in a phase 2 for healthy and Cystic Fibrosis patients since 2014, and in February terminated the trial prior to completion, and readout. The link is NCT02190604. QBW251 was one of a few potentiators that are being tested for efficacy. Perhaps Novartis may see some value in potentiator CTP-656, once the company completes their phase 2 clinical trial sometime in 2017. Thank you for reading.
